

VALUE-BASED CONTRACTS: 2009 – Q2 2018

This list includes value-based contracts (VBC) executed and publicly announced in the United States from 2009-2018. This list includes public program VBCs to the extent that they are modeled similarly to commercial contracts, but does not include other public program contracts that may be seen as types of VBCs (e.g., Coverage with Evidence Development). This list is not comprehensive; we believe many VBCs are executed without the release of publicly available information. New information will be added as it becomes available.

This list is current as of June 21, 2018

	Brand Name	Non-Proprietary Name	Year	Therapeutic Area	Disease Area	Biopharmaceutical Company	Payer
1	Xtampza ER	Oxycodone	2018	Opioids	Pain management	Collegium Pharmaceutical	Cigna
2	Jardiance	Empagliflozin	2018	Endocrinology	Diabetes	Boehringer Ingelheim	Highmark
3	Jardiance	Empagliflozin	2018	Endocrinology	Diabetes	Boehringer Ingelheim	Prime Therapeutics
4	Luxturna	Voretigene Neparvovec-rzyl	2018	Ophthalmology	Retinal Disease	Spark Therapeutics	Harvard Pilgrim Health Care
5	Luxturna	Voretigene Neparvovec-rzyl	2018	Ophthalmology	Retinal Disease	Spark Therapeutics	Express Scripts
6	Symbicort	Budesonide/ Formoterol	2018	Respiratory	COPD	AstraZeneca	Harvard Pilgrim
7	Symbicort	Budesonide/ Formoterol	2018	Respiratory	COPD	AstraZeneca	Highmark
8	Victoza	Liraglutide	2018	Endocrinology	Diabetes	Novo Nordisk	SelectHealth
9	Brilinta	Ticagrelor	2017	Cardiovascular Disease	Cardiovascular Disease	AstraZeneca	Harvard Pilgrim Health Care
10	Bydureon	Exenatide	2017	Endocrinology	Diabetes	AstraZeneca	Harvard Pilgrim Health Care
11	Enbrel	Etanercept	2017	Rheumatology	Rheumatoid Arthritis	Amgen	Harvard Pilgrim Health Care
12	Forteo	Teriparatide	2017	Musculoskeletal	Osteoporosis	Eli Lilly	Harvard Pilgrim Health Care
13	Janumet/ Januvia	Sitagliptin/Metformin	2017	Endocrinology	Diabetes	Merck	Aetna
14	Kymriah	Tisagenlecleucel	2017	Oncology	Acute Lymphoblastic Leukemia	Novartis	Unspecified
15	Unspecified (MS)	Unspecified (MS)	2017	Neurology	Multiple Sclerosis	Biogen	SelectHealth
16	Unspecified (MS)	Unspecified (MS)	2017	Neurology	Multiple Sclerosis	Biogen	Harvard Pilgrim
17	Unspecified (MS)	Unspecified (MS)	2017	Neurology	Multiple Sclerosis	Biogen	Moda Health
18	Unspecified (MS)	Unspecified (MS)	2017	Neurology	Multiple Sclerosis	Biogen	Abarca Health
19	Victoza	Liraglutide	2017	Endocrinology	Diabetes	Novo Nordisk	Humana
20	Effient	Prasugrel	2016	Cardiology	Cardiovascular Disease	Eli Lilly	Humana
21	Entresto	Sacubitril and Valsartan	2016	Cardiology	Heart Failure	Novartis	Cigna

VALUE-BASED CONTRACTS: 2009 – Q2 2018

This list includes value-based contracts (VBC) executed and publicly announced in the United States from 2009-2018. This list includes public program VBCs to the extent that they are modeled similarly to commercial contracts, but does not include other public program contracts that may be seen as types of VBCs (e.g., Coverage with Evidence Development). This list is not comprehensive; we believe many VBCs are executed without the release of publicly available information. New information will be added as it becomes available.

This list is current as of June 21, 2018

22	Entresto	Sacubitril and Valsartan	2016	Cardiology	Heart Failure	Novartis	Aetna
23	Entresto	Sacubitril and Valsartan	2016	Cardiology	Heart Failure	Novartis	Harvard Pilgrim Health Care
24	Praluent	Alirocumab	2016	Cardiology	Hypercholesterolemia	Sanofi, Regeneron	Cigna
25	Repatha	Evolocumab	2016	Cardiology	Hypercholesterolemia	Amgen	Cigna
26	Trulicity	Dulaglutide	2016	Endocrinology	Diabetes	Eli Lilly	Harvard Pilgrim Health Care
27	Avastin	Bevacizumab	2015	Oncology	Non-small-cell Lung Cancer (NSCLC)	Genentech	Priority Health
28	Brilinta	Ticagrelor	2015	Cardiovascular Disease	Cardiovascular Disease	AstraZeneca	University of Pittsburgh Medical Center
29	Harvoni	Ledipasvir-sofosbuvir	2015	Infectious Diseases	Hepatitis C	Gilead	Cigna
30	Harvoni	Ledipasvir-sofosbuvir	2015	Infectious Diseases	Hepatitis C	Gilead	Optum
31	Iressa	Gefitinib	2015	Oncology	Lung Cancer	AstraZeneca	Express Scripts
32	Praluent	Alirocumab	2015	Endocrinology	Familial Hypercholesterolemia	Sanofi, Regeneron	Prime Therapeutics
33	Repatha	Evolocumab	2015	Endocrinology	Familial Hypercholesterolemia	Amgen	Harvard Pilgrim Health Care
34	Repatha	Evolocumab	2015	Endocrinology	Familial Hypercholesterolemia	Amgen	Prime Therapeutics
35	Repatha	Evolocumab	2015	Cardiology	Hypercholesterolemia	Amgen	CVS Health
36	Viekira Pak	Dasabuvir, Ombitasvir, Paritaprevir, and Ritonavir	2015	Infectious Diseases	Hepatitis C	AbbVie	Express Scripts
37	Rebif	Interferon Beta-1a	2012	Neurology	Multiple Sclerosis	EMD Serono	Prime Therapeutics
38	Actonel	Risedronate	2011	Endocrinology	Osteoporosis	Warner Chilcott	Prime Therapeutics
39	Betaseron	Interferon Beta-1b	2011	Neurology	Multiple Sclerosis	Bayer HealthCare Pharmaceuticals	Health Alliance Medical Plans, Inc.
40	Januvia	Sitagliptin	2011	Endocrinology	Diabetes	Merck	Prime Therapeutics
41	Rebif	Interferon Beta-1a	2011	Neurology	Multiple Sclerosis	EMD Serono	Cigna
42	Actonel	Risedronate	2009	Endocrinology	Osteoporosis	Proctor and Gamble	Health Alliance
43	Janumet/Januvia	Metformin/Sitagliptin	2009	Endocrinology	Diabetes	Merck	Cigna